<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00032487</url>
  </required_header>
  <id_info>
    <org_study_id>465</org_study_id>
    <nct_id>NCT00032487</nct_id>
  </id_info>
  <brief_title>Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)</brief_title>
  <acronym>VADT</acronym>
  <official_title>CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>SmithKline Beecham</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic
      control, achieved through intensification of treatment, is effective in preventing clinical
      macrovascular complications in patients with type 2 DM who are no longer responsive to oral
      agents alone. The study consists of a two-year accrual period and five years of follow-up (7
      years total) of 1700 patients across 20 centers. We have powered the study to detect a 21%
      reduction in the primary event rate. Additional study goals are to determine whether the
      expenditures, discomfort, and adverse effects associated with intensive intervention are
      justified in terms of their clinical benefits, considering both macrovascular and
      microvascular complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Hypothesis: Intensive glycemic control reduces major macrovascular morbidity and
      mortality compared to standard glycemic control in type 2 diabetics who have failed simple
      therapy.

      Secondary Hypotheses: Intensive glycemic control, compared to standard glycemic control,
      reduces other macrovascular morbidity and total mortality.

      Intervention: The intervention is tight glycemic control, aiming at normalization of HbA1c.
      This will be achieved through stepped care therapy, using all categories of tools available
      to most diabetologists. These categories include: patient education of diabetes control (e.g.
      diet, exercise, etc.), oral diabetes medications, and insulin. All drugs to be used are
      approved. Specific agents will be used within the different classes to promote consistency
      across sites.

      The comparison is standard control, aiming at HbA1c of 8 - 9%. The same agents will be used,
      but at reduced doses.

      The general approach to the stepped care treatment protocol is to treat both groups with the
      same agents, but at different intensities (doses) (taking into account
      intolerance/contraindications). The sequence of steps is shown below.

      STEP 1: Either Metformin (obese) or Glimepiride (lean)in combination with Rosiglitazone STEP
      2: Insulin STEP 3: Increase doses in STEPS 1,2 in the Standard group. Since the Intensive
      group is already at maximal doses of oral agents, they will intensify insulin and may add
      Acarbose/Miglitol.

      STEP 4: For standard, proceed as in STEP 3 for Intensive; Intensives will use multiple daily
      injection (MDI) of insulin STEP 5: &quot;Tool Box&quot;: Miscellaneous agents, tailored to the
      individual patient.

      Primary Outcomes: Time to one of the following major macrovascular events: myocardial
      infarction, stroke, new or worsening congestive heart failure, amputation for ischemic
      gangrene, invasive intervention for coronary artery or peripheral vascular disease,
      inoperable coronary artery disease, or cardiovascular death.

      Secondary Outcomes: Angina, transient ischemic attack, intermittent claudication, critical
      limb ischemia, and total mortality.

      Study Abstract: A quarter of the patients treated by the Department of Veterans Affairs (VA)
      Health Administration have type 2 diabetes mellitus (DM). The costs of care for the treatment
      of patients with type 2 DM are extremely high, both in treatment expenditures for the
      metabolic disorder and for the care of end-organ complications. Although patients initially
      respond to diet and oral agent treatment, most eventually need insulin to near-normalize
      their glucose level, as the disease is characterized by progressive loss of insulin secretory
      capacity.

      After several clinical trials in both type 1 and type 2 DM, there is a reasonable certainty
      that about half of the incidence and rate of progression of indicators of microvascular
      complications (retinopathy, nephropathy, and neuropathy) can be prevented or delayed by
      achieving and maintaining near-normalization of glycemic levels. Consequently, there has been
      a uniform trend in recent guidelines to advise a near-normalization of glycemic levels in
      both type 1 and type 2 DM. Note, however, that the clinical consequences of microvascular
      deterioration are dependent not only on glycemic levels but also on the duration of the
      disease. With the early onset of diabetes typical in type 1 patients, there is sufficient
      time for development of clinical microvascular complications, and prevention of these
      complications is a goal of treatment in type 1 diabetics. In contrast, the prevalence of hard
      clinical endpoints indicative of microangiopathy, such as renal failure or blindness, is very
      low in patients in whom the disease is diagnosed after the 5th decade, the greatest age of
      prevalence of patients with type 2 DM in this country. Furthermore, microvascular
      complications can be minimized by the well-established benefits of blood pressure and lipid
      control, as well as by therapeutic intervention (photocoagulation, cataract extraction).
      Since the costs and efforts necessary to reach near-normal levels of glycemia are very high,
      there is a need to determine the cost/benefit ratios of such expenditures in the population
      subject to type 2 diabetes, namely patients in their 6th to 8th decades of life.

      In contrast with the late and relatively infrequent appearance of clinical endpoints of
      microangiopathy, macrovascular complications (i.e., coronary heart disease and peripheral
      vascular disease) are responsible for the overwhelming majority of the mortality, morbidity
      and treatment costs in the American population of type 2 diabetics, even more so in the older
      VA diabetic population. In the recently concluded United Kingdom Prospective Diabetes Study
      (UKPDS) on type 2 DM, macrovascular mortality was 70 times higher than that of microvascular
      mortality. Intervention studies to determine the effect of rigorous glycemic control on these
      macrovascular events are inconclusive and contradictory. Intensive treatment in patients who
      are newly diagnosed has failed to demonstrate a beneficial effect of tight control on
      cardiovascular complications. The few studies conducted in later stages of the disease (i.e.,
      in patients requiring insulin treatment, alone or in combination with oral agents) have been
      conflicting and indeterminate.

      The decision on intensity of treatment is further compromised by current recommendations to
      attenuate glycemic control goals, especially when usage of insulin is required, both in
      patients with the common comorbidities of overweight or preexisting cardiovascular disease,
      and in those in the later decades of life. These concerns are based on fears that intensive
      insulin treatment might be associated with weight gain, increased cardiovascular risk factors
      (hypertriglyceridemia, dyslipidemia, hyperinsulinemia, and insulin resistance), and adverse
      effects of recurrent hypoglycemic events. The prevalent level of glycemic control in
      insulin-treated type 2 diabetics is relatively poor, likely due to a combination of practical
      difficulties and the uncertainties of what are the safe and effective glycemic goals. There
      is no long-term study currently being done in the high-risk population typical of the patient
      population in the VA. Before the Department of Veterans Affairs devotes considerable
      resources to a widespread intervention (a quarter of patients) that may be of little value,
      and might even be counterproductive, a trial to determine the value of the intervention is
      mandated. It is expected that CSP #465 will provide the scientific data on which the VA can
      base clinical treatment of Type II diabetes.

      CSP #465 is a prospective, 2-arm, randomized controlled trial to determine whether glycemic
      control, achieved through intensification of treatment, is effective in preventing clinical
      macrovascular complications in patients with type 2 DM who are no longer responsive to oral
      agents alone. The study consists of a two-year accrual period and five years of follow-up (7
      years total) of 1700 patients across 20 centers. We have powered the study to detect a 25%
      reduction in the primary event rate. Additional study goals are to determine whether the
      expenditures, discomfort, and adverse effects associated with intensive intervention are
      justified in terms of their clinical benefits, considering both macrovascular and
      microvascular complications.

      Main Manuscript:Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N et al., VADT
      investigators: Glucose Control and Complications in the VA Diabetes Trial (VADT). N Eng J of
      Med 360:129-139, 2009.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2000</start_date>
  <completion_date type="Actual">May 30, 2008</completion_date>
  <primary_completion_date type="Actual">May 30, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Major Macrovascular Events</measure>
    <time_frame>Post baseline time to the first major macrovascular event up to 82 months</time_frame>
    <description>Myocardial infarction (MI), intervention for coronary artery or Peripheral Vascular Disease (PVD), severe inoperable Coronary Artery Disease (CAD), new or worsening Congestive Heart Failure (CHF), stroke, Cardiovascular (CV) death, or amputation for ischemic gangrene.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>Post baseline time to first event up to 82 months</time_frame>
    <description>New or worsening angina, new transient ischemic attack (TIA), new intermittent claudication or critical limb ischemia with Doppler evidence or total mortality.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1791</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Standard glycemic control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive glycemic control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2</description>
    <arm_group_label>Standard glycemic control</arm_group_label>
    <arm_group_label>Intensive glycemic control</arm_group_label>
    <other_name>Lente</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2</description>
    <arm_group_label>Standard glycemic control</arm_group_label>
    <arm_group_label>Intensive glycemic control</arm_group_label>
    <other_name>Amaryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2</description>
    <arm_group_label>Standard glycemic control</arm_group_label>
    <arm_group_label>Intensive glycemic control</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm</description>
    <arm_group_label>Standard glycemic control</arm_group_label>
    <arm_group_label>Intensive glycemic control</arm_group_label>
    <other_name>Glumetza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 DM who are no longer responsive to maximum dose of one or more
             oral agents.

        Exclusion Criteria:

          -  Angina pectoris, Canadian Class I-II,

          -  congestive heart failure, Class III-IV,

          -  stroke, incapacitating or in last 6 months,

          -  Myocardial infarction (MI) or invasive cardiovascular procedure within the past six
             months,

          -  ongoing diabetic gangrene,

          -  BMI &gt; 40,

          -  hemoglobinopathy that interferes with A1c monitoring,

          -  serum creatinine &gt; 1.6 mg/dL,

          -  fasting C-peptide &lt; 0.21 pmol/ml,

          -  Alanine Amino Transaminase (ALT) &gt; 3 times normal or serum bilirubin &gt; 1.9 mg/dL,

          -  malignancy or noncardiac life-threatening diseases making life expectancy &lt; 5 years,

          -  autonomic neuropathy,

          -  symptomatic pancreatic insufficiency (endocrine or exocrine),

          -  recurrent seizures within the past year,

          -  hypopituitarism,

          -  pregnancy, lactation, or planning a pregnancy,

          -  active psychosis or substance abuse,

          -  lack of access to a person who can assist or be called in an emergency,

          -  underlying conditions that in the site PI's judgment may prevent adherence to
             protocol,

          -  current participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Abraira, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Miami VA Healthcare System, Miami, FL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Duckworth, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Phoenix VA Health Care System, Phoenix, AZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carl T. Hayden VA Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Arizona VA Health Care System, Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Central California Health Care System, Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami VA Healthcare System, Miami, FL</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hines, Jr. VA Hospital</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard Roudebush VA Medical Center, Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-2884</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105-1873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA New Jersey Health Care System, East Orange</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Health Care System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralph H Johnson VA Medical Center, Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401-5799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-2637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center (152)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA South Texas Health Care System, San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Salem VA</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System, Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, San Juan</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39. doi: 10.1056/NEJMoa0808431. Epub 2008 Dec 17. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1028. N Engl J Med. 2009 Sep 3;361(10):1024-5.</citation>
    <PMID>19092145</PMID>
  </results_reference>
  <results_reference>
    <citation>Moritz T, Duckworth W, Abraira C. Veterans Affairs diabetes trial--corrections. N Engl J Med. 2009 Sep 3;361(10):1024-5. doi: 10.1056/NEJMc096250.</citation>
    <PMID>19726779</PMID>
  </results_reference>
  <results_reference>
    <citation>Emanuele N, Moritz T, Klein R, Davis MD, Glander K, Khanna A, Thottapurathu L, Bahn G, Duckworth W, Abraira C; Veterans Affairs Diabetes Trial Study Group. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Res Clin Pract. 2009 Nov;86(2):104-10. doi: 10.1016/j.diabres.2009.08.001. Epub 2009 Aug 31.</citation>
    <PMID>19720420</PMID>
  </results_reference>
  <results_reference>
    <citation>Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009 Nov;52(11):2288-98. doi: 10.1007/s00125-009-1470-0. Epub 2009 Aug 5. Erratum in: Diabetologia. 2009 Nov;52(1):2470. Control Group [added].</citation>
    <PMID>19655124</PMID>
  </results_reference>
  <results_reference>
    <citation>Abraira C, Duckworth WC, Moritz T; VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab. 2009 Feb;11(2):150-6. doi: 10.1111/j.1463-1326.2008.00933.x. Epub 2008 Jul 29.</citation>
    <PMID>18671796</PMID>
  </results_reference>
  <results_reference>
    <citation>Emanuele N, Klein R, Moritz T, Davis MD, Glander K, Anderson R, Reda D, Duckworth W, Abraira C; VADT Study Group. Comparison of dilated fundus examinations with seven-field stereo fundus photographs in the Veterans Affairs Diabetes Trial. J Diabetes Complications. 2009 Sep-Oct;23(5):323-9. doi: 10.1016/j.jdiacomp.2008.02.010. Epub 2008 Apr 11.</citation>
    <PMID>18406632</PMID>
  </results_reference>
  <results_reference>
    <citation>Meyers CD, McCarren M, Wong ND, Abraira C, Duckworth WC, Kashyap ML; VADT Investigators. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). Am J Cardiol. 2006 Jul 1;98(1):63-5. Epub 2006 May 4.</citation>
    <PMID>16784922</PMID>
  </results_reference>
  <results_reference>
    <citation>Duckworth WC, McCarren M, Abraira C; VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocr Pract. 2006 Jan-Feb;12 Suppl 1:85-8. Review.</citation>
    <PMID>16627388</PMID>
  </results_reference>
  <results_reference>
    <citation>Kirkman MS, McCarren M, Shah J, Duckworth W, Abraira C; VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. J Diabetes Complications. 2006 Mar-Apr;20(2):75-80.</citation>
    <PMID>16504835</PMID>
  </results_reference>
  <results_reference>
    <citation>Emanuele N, Sacks J, Klein R, Reda D, Anderson R, Duckworth W, Abraira C; Veterans Affairs Diabetes Trial Group. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care. 2005 Aug;28(8):1954-8.</citation>
    <PMID>16043738</PMID>
  </results_reference>
  <results_reference>
    <citation>Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D, Henderson W; VA Cooperative Study of Glycemic Control and Complications in Diabetes Mellitus Type 2. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications. 2003 Nov-Dec;17(6):314-22.</citation>
    <PMID>14583175</PMID>
  </results_reference>
  <results_reference>
    <citation>Duckworth WC, McCarren M, Abraira C; VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care. 2001 May;24(5):942-5.</citation>
    <PMID>11347758</PMID>
  </results_reference>
  <results_reference>
    <citation>Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abraira C, Duckworth W; VADT Study Group. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2011 Jan;34(1):34-8. doi: 10.2337/dc10-1420. Epub 2010 Nov 8.</citation>
    <PMID>21059830</PMID>
  </results_reference>
  <results_reference>
    <citation>Agrawal L, Azad N, Emanuele NV, Bahn GD, Kaufman DG, Moritz TE, Duckworth WC, Abraira C; Veterans Affairs Diabetes Trial (VADT) Study Group. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care. 2011 Sep;34(9):2090-4. doi: 10.2337/dc11-0175. Epub 2011 Jul 20.</citation>
    <PMID>21775749</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2002</study_first_submitted>
  <study_first_submitted_qc>March 21, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2002</study_first_posted>
  <results_first_submitted>September 10, 2013</results_first_submitted>
  <results_first_submitted_qc>December 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2014</results_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DM</keyword>
  <keyword>glycemic control</keyword>
  <keyword>insulin</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty Veterans Affairs Medical Centers (VAMCs) were selected to participate in this cooperative study. The recruitment period was from 12/01/00 to 05/31/03.</recruitment_details>
      <pre_assignment_details>A patient had to meet all the screening criteria for eligibility and had to sign a consent form with blood samples and meet all entry criteria for pre-randomization testing. Once the patient was deemed appropriate for the study, Hines completed the randomization assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Glycemic Control</title>
          <description>Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs</description>
        </group>
        <group group_id="P2">
          <title>Intensive Glycemic Control</title>
          <description>Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="899"/>
                <participants group_id="P2" count="892"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="760"/>
                <participants group_id="P2" count="772"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Had other reason</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1/Standard Glycemic Control</title>
          <description>Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs</description>
        </group>
        <group group_id="B2">
          <title>Arm 2/Intensive Glycemic Control</title>
          <description>Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Standard glycemic control</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="899"/>
            <count group_id="B2" value="892"/>
            <count group_id="B3" value="1791"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="606"/>
                    <measurement group_id="B2" value="612"/>
                    <measurement group_id="B3" value="1218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="280"/>
                    <measurement group_id="B3" value="573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="9.0"/>
                    <measurement group_id="B2" value="60.5" spread="9.0"/>
                    <measurement group_id="B3" value="60.4" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="873"/>
                    <measurement group_id="B2" value="866"/>
                    <measurement group_id="B3" value="1739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="899"/>
                    <measurement group_id="B2" value="892"/>
                    <measurement group_id="B3" value="1791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Major Macrovascular Events</title>
        <description>Myocardial infarction (MI), intervention for coronary artery or Peripheral Vascular Disease (PVD), severe inoperable Coronary Artery Disease (CAD), new or worsening Congestive Heart Failure (CHF), stroke, Cardiovascular (CV) death, or amputation for ischemic gangrene.</description>
        <time_frame>Post baseline time to the first major macrovascular event up to 82 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Major Macrovascular Events</title>
          <description>Myocardial infarction (MI), intervention for coronary artery or Peripheral Vascular Disease (PVD), severe inoperable Coronary Artery Disease (CAD), new or worsening Congestive Heart Failure (CHF), stroke, Cardiovascular (CV) death, or amputation for ischemic gangrene.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="899"/>
                <count group_id="O2" value="892"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized 21% reduction in intensive glycemic control group compared to standard control group on primary cardiovascular composite outcomes.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The statistical analysis tested was for equivalence. We assumed 86% power with 21% of effect size and the sample size 1700 with 5% drop out rate.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.79</ci_lower_limit>
            <ci_upper_limit>.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint</title>
        <description>New or worsening angina, new transient ischemic attack (TIA), new intermittent claudication or critical limb ischemia with Doppler evidence or total mortality.</description>
        <time_frame>Post baseline time to first event up to 82 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint</title>
          <description>New or worsening angina, new transient ischemic attack (TIA), new intermittent claudication or critical limb ischemia with Doppler evidence or total mortality.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="899"/>
                <count group_id="O2" value="892"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283"/>
                    <measurement group_id="O2" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were collected in a 82-month period.</time_frame>
      <desc>Adverse events were reported by staff at visits or the patient between visits. Staff submitted an Adverse event report, using the FDA Form 3500, for each patient with a severe or unexpected reaction that may reasonably be treatment-related. Reports were screened by the research pharmacist and Study Co-Chairs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="899"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic Disorders</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="899"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="899"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, familial and genetic Disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="899"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine Disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="899"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="899"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="899"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="899"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary Disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="899"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="81" subjects_affected="81" subjects_at_risk="899"/>
                <counts group_id="E2" events="71" subjects_affected="71" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="899"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="899"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and Nutrition Disorders</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="899"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="899"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="899"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System Disorders</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="899"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric Disorders</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="899"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and Urinary Disorders</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="899"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and brest Disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="899"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal Disorders</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="899"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue Disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="899"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and Medical Procedures</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="899"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Disorders</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="899"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="730" subjects_at_risk="899"/>
                <counts group_id="E2" subjects_affected="675" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood</sub_title>
                <counts group_id="E1" events="67" subjects_affected="67" subjects_at_risk="899"/>
                <counts group_id="E2" events="87" subjects_affected="87" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="69" subjects_affected="69" subjects_at_risk="899"/>
                <counts group_id="E2" events="62" subjects_affected="62" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear</sub_title>
                <counts group_id="E1" events="61" subjects_affected="61" subjects_at_risk="899"/>
                <counts group_id="E2" events="52" subjects_affected="52" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders</sub_title>
                <counts group_id="E1" events="185" subjects_affected="185" subjects_at_risk="899"/>
                <counts group_id="E2" events="183" subjects_affected="183" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Disorders</sub_title>
                <counts group_id="E1" events="288" subjects_affected="288" subjects_at_risk="899"/>
                <counts group_id="E2" events="289" subjects_affected="289" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="315" subjects_affected="315" subjects_at_risk="899"/>
                <counts group_id="E2" events="290" subjects_affected="290" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune</sub_title>
                <counts group_id="E1" events="67" subjects_affected="67" subjects_at_risk="899"/>
                <counts group_id="E2" events="58" subjects_affected="58" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="385" subjects_affected="385" subjects_at_risk="899"/>
                <counts group_id="E2" events="354" subjects_affected="354" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="235" subjects_affected="235" subjects_at_risk="899"/>
                <counts group_id="E2" events="227" subjects_affected="227" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="167" subjects_affected="167" subjects_at_risk="899"/>
                <counts group_id="E2" events="174" subjects_affected="174" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism</sub_title>
                <counts group_id="E1" events="115" subjects_affected="115" subjects_at_risk="899"/>
                <counts group_id="E2" events="132" subjects_affected="132" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="493" subjects_affected="493" subjects_at_risk="899"/>
                <counts group_id="E2" events="480" subjects_affected="480" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms</sub_title>
                <counts group_id="E1" events="78" subjects_affected="78" subjects_at_risk="899"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system</sub_title>
                <counts group_id="E1" events="318" subjects_affected="318" subjects_at_risk="899"/>
                <counts group_id="E2" events="283" subjects_affected="283" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="175" subjects_affected="175" subjects_at_risk="899"/>
                <counts group_id="E2" events="166" subjects_affected="166" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="138" subjects_affected="138" subjects_at_risk="899"/>
                <counts group_id="E2" events="158" subjects_affected="158" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive</sub_title>
                <counts group_id="E1" events="82" subjects_affected="82" subjects_at_risk="899"/>
                <counts group_id="E2" events="62" subjects_affected="62" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="227" subjects_affected="227" subjects_at_risk="899"/>
                <counts group_id="E2" events="218" subjects_affected="218" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" events="214" subjects_affected="214" subjects_at_risk="899"/>
                <counts group_id="E2" events="206" subjects_affected="206" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical</sub_title>
                <counts group_id="E1" events="77" subjects_affected="77" subjects_at_risk="899"/>
                <counts group_id="E2" events="89" subjects_affected="89" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="115" subjects_affected="115" subjects_at_risk="899"/>
                <counts group_id="E2" events="90" subjects_affected="90" subjects_at_risk="892"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our study had several limitations. Since we were studying veterans, the patients were predominantly men, and extrapolation of our findings to women must be done with caution.Changes in therapeutic agents have occurred since the design of our protocol</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Project Manager</name_or_title>
      <organization>Hines CSPCC</organization>
      <phone>708-202-5785</phone>
      <email>tamara.paine@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

